Inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: a prospective, single-arm, phase 2 study

Puntos clave

• Treatment response observed with combination therapy in advanced breast cancer patients, highlighting its potential effectiveness.
• The study evaluates the effects of inetetamab, camrelizumab, and utidelone on tumor progression over a defined period.
• This approach includes immune checkpoint inhibition and targets HER2-positive tumors, aiming for improved outcomes.
• Findings support the need for diverse treatment strategies in complex cancer cases, particularly for pretreated patients.